Aetna modified CPB 0200 governing heparin bridge therapy coverage, effective September 26, 2025. Here's what billing teams need to know before submitting claims for J1642, J1643, J1644, or S9336.
Aetna, a CVS Health company, updated its anticoagulant conversion policy under CPB 0200 in the Aetna heparin bridge therapy coverage policy. This change clarifies medical necessity standards for continuous IV heparin infusion in members taking apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), rivaroxaban (Xarelto), or warfarin who need anticoagulation maintained around elective procedures. The four HCPCS codes directly affected are J1642, J1643, J1644, and S9336, along with ICD-10-CM diagnosis code Z79.01.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Conversion of Anti-Coagulants to Heparin Before and After Elective Surgery |
| Policy Code | CPB 0200 |
| Change Type | Modified |
| Effective Date | 2025-09-26 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Hematology, General Surgery, Interventional Radiology, Hospital Medicine, Home Infusion |
| Key Action | Audit active claims for J1644 and S9336 against Z79.01 and confirm inpatient pre-procedure days do not exceed three without documented thrombotic risk |
Aetna Heparin Bridge Therapy Coverage Criteria and Medical Necessity Requirements 2025
The core of the CPB 0200 Aetna coverage policy is straightforward: continuous IV heparin infusion is medically necessary when a member on oral anticoagulation needs that anticoagulation maintained before or after a diagnostic or therapeutic procedure. That covers all five major oral anticoagulants — apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin.
The policy draws a clear line on the outpatient default. For most members, Aetna expects pre-procedure weaning to happen on an outpatient basis. This is not a soft preference. If your team is routinely billing inpatient pre-procedure days without documented clinical justification, those claims are at risk.
Inpatient pre-procedure coverage kicks in only when specific circumstances threaten the member's anticoagulation status and create real thrombotic risk. When that threshold is met, up to three inpatient pre-procedure days are covered. Not four. Not "up to a week depending on complexity." Three days is the ceiling under this coverage policy.
Medical necessity documentation needs to reflect the clinical rationale clearly. Vague notes about the patient being "high risk" will not support an inpatient admission under this policy. Your physicians need to document the specific circumstances — the condition, the procedural risk, and why outpatient weaning is unsafe — to support the inpatient level.
This policy does not mention prior authorization requirements explicitly. That said, inpatient admissions billed under this framework should still go through your standard prior auth workflow for Aetna surgical cases. If your facility has a specific authorization pathway for pre-procedure heparin bridges, confirm it aligns with the September 26, 2025 effective date criteria before billing.
For home infusion teams billing S9336, the outpatient default actually supports your reimbursement pathway. Aetna's position that most members can wean safely outside the hospital is an implicit endorsement of home infusion therapy for anticoagulant bridging. S9336 covers continuous anticoagulant infusion therapy administered at home, and it sits squarely within Aetna's stated clinical framework here.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Continuous IV heparin infusion for member on apixaban (Eliquis) requiring anticoagulation maintenance around a procedure | Covered | J1644, Z79.01 | Outpatient preferred; inpatient only with documented thrombotic risk |
| Continuous IV heparin infusion for member on dabigatran (Pradaxa) | Covered | J1644, Z79.01 | Same outpatient-first standard applies |
| Continuous IV heparin infusion for member on edoxaban (Savaysa) | Covered | J1644, Z79.01 | Same outpatient-first standard applies |
| Continuous IV heparin infusion for member on rivaroxaban (Xarelto) | Covered | J1644, Z79.01 | Same outpatient-first standard applies |
| Continuous IV heparin infusion for member on warfarin | Covered | J1644, Z79.01 | Same outpatient-first standard applies |
| Heparin lock flush around procedure for anticoagulated member | Covered if criteria met | J1642, Z79.01 | Must meet same medical necessity threshold |
| Heparin sodium (Pfizer) injection, not therapeutically equivalent to J1644 | Covered if criteria met | J1643, Z79.01 | Non-equivalent product; document clinical basis for use |
| Home infusion — continuous anticoagulant infusion therapy | Covered if criteria met | S9336, Z79.01 | Consistent with Aetna's outpatient-first position |
| Inpatient pre-procedure heparin bridge — up to 3 days | Covered if criteria met | J1644, Z79.01 | Requires documentation of circumstances threatening anticoagulation stability |
| Inpatient pre-procedure stay exceeding 3 days | Not covered under CPB 0200 | — | Beyond policy ceiling; would require separate clinical justification |
Aetna Heparin Bridge Therapy Billing Guidelines and Action Items 2025
These are the steps your billing team needs to take now — before and after the September 26, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Audit your inpatient pre-procedure claims for heparin bridge therapy. Pull every claim billed with J1644 tied to a pre-procedure inpatient stay. If any show more than three inpatient days, flag them for clinical documentation review. Aetna's three-day ceiling is firm. |
| 2 | Confirm Z79.01 is on every claim. Every heparin infusion claim under this policy — whether J1642, J1643, J1644, or S9336 — needs ICD-10-CM Z79.01 (long-term use of anticoagulants) as a supporting diagnosis. Missing this code is a clean path to a claim denial. Build it into your charge capture workflow if it isn't there already. |
| 3 | Train your clinical documentation team on the inpatient threshold. The difference between outpatient and inpatient coverage here is documentation-driven. Physicians need to explicitly record the clinical circumstances that create thrombotic risk when outpatient weaning is not appropriate. Generic risk language will not hold up on appeal. |
| 4 | Review your S9336 billing process for home infusion heparin. S9336 is your code for home-based continuous anticoagulant infusion. Given that Aetna's coverage policy defaults to outpatient management, this code has solid ground to stand on. Confirm your home infusion team is capturing it correctly and pairing it with Z79.01 and appropriate procedure context. |
| 5 | Check for J1643 use cases and document the clinical rationale. J1643 covers heparin sodium (Pfizer) that is not therapeutically equivalent to J1644. If your facility uses this product, your claims need to reflect the clinical basis for choosing a non-equivalent formulation. Aetna will cover it when criteria are met, but "criteria are met" means documented, not assumed. |
| 6 | Verify your prior auth process aligns with the updated policy. CPB 0200 does not spell out a specific prior authorization requirement for heparin bridge therapy. But inpatient pre-procedure admissions involving these HCPCS codes still need to move through your standard Aetna authorization pathway. Confirm your utilization management team knows what clinical criteria now apply as of September 26, 2025. |
| 7 | Set a claims review checkpoint for Q4 2025. The effective date is September 26, 2025. Pull a 30-day sample of post-effective-date claims for J1642, J1643, J1644, and S9336 in October or November. Look for denial patterns that suggest documentation gaps or miscoded inpatient days. Fix the process before denials accumulate. |
If your facility handles a high volume of anticoagulated surgical patients, this policy touches a meaningful slice of your revenue cycle. Talk to your compliance officer about whether your current documentation templates meet the "thrombotic complication risk" standard Aetna now requires for inpatient approval.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Heparin Bridge Therapy Under CPB 0200
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J1642 | HCPCS | Injection, heparin sodium (Heparin Lock Flush), per 10 units |
| J1643 | HCPCS | Injection, heparin sodium (Pfizer), not therapeutically equivalent to J1644, per 1,000 units |
| J1644 | HCPCS | Injection, heparin sodium, per 1,000 units |
| S9336 | HCPCS | Home infusion therapy, continuous anticoagulant infusion therapy (e.g., heparin), administrative services, nursing services, supplies and equipment (per diem) |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| Z79.01 | Long term (current) use of anticoagulants |
A few notes on code selection that matter for heparin bridge therapy billing:
J1643 versus J1644 — These are not interchangeable. J1643 is specifically for the Pfizer heparin sodium product and is flagged as not therapeutically equivalent to J1644. Bill the wrong code for the product dispensed and you're looking at a claim denial or audit exposure. Check your pharmacy records.
S9336 for home infusion — This code includes administrative services, nursing services, supplies, and equipment on a per-diem basis. It is a bundled code. Do not also bill separately for the nursing visit or supplies already included in the S9336 rate. Unbundling here is a billing error with compliance implications.
Z79.01 is doing real work here. It is not a secondary throwaway code. This is the ICD-10-CM code that tells Aetna the member is chronically anticoagulated — the entire clinical basis for bridge therapy coverage under CPB 0200. Omit it, and the claim has no diagnostic support for the procedure.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.